Cell-mediated immune resistance in cancer

Abstract

The genetic and epigenetic aberrations that underlie immune resistance lead to tumors that are refractory to clinically established and experimental immunotherapies, including monoclonal antibodies and T cell-based therapies. From various forms of cytotoxic T cells to small molecule inhibitors that revamp the tumor microenvironment, these therapies have demonstrated notable responses in cancer models and a resistant subset of cancer patients, used both alone and in combination. However, even current approaches, such as those targeting checkpoint molecules, tumor ligands, and involving gene-related therapies, present a challenge in non-responding patients. In this perspective, we discuss the most common mechanisms of immune resistance, including tumor heterogeneity, tumor ligand and major histocompatibility complex modulation, anti-apoptotic pathways, checkpoint inhibitory ligands, immunosuppressive cells and factors in the tumor microenvironment, and activation-induced cell death. In addition, we discuss the strategies designed to circumvent these resistance pathways to showcase the potential of emerging technologies in battling the rise of resistance.

Keywords

Immune system / immune resistance / survival pathways / heterogeneity / cancer / T cells / checkpoint inhibitors / tumor microenvironment

References

[1] Vesely MD,Schreiber RD.Natural innate and adaptive immunity to cancer..Annu Rev Immunol2011;29:235-71

[2] Imai K,Miyake S,Nakachi K.Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population..Lancet2000;356:1795-9

[3] Corrales L,Flood B,Gajewski TF.Innate immune signaling and regulation in cancer immunotherapy..Cell Res2017;27:96-108 PMCID:PMC5223230

[4] Bonavida B.Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance..Ann Oncol2017;28:457-67 PMCID:PMC5834050

[5] Bonaventura P,Alcazer V,Valsesia-Wittmann S.Cold tumors: a therapeutic challenge for immunotherapy..Front Immunol2019;10:168 PMCID:PMC6376112

[6] Banchereau J.Dendritic cells as therapeutic vaccines against cancer..Nat Rev Immunol2005;5:296-306

[7] Ueno H,Palucka AK.Dendritic cells and humoral immunity in humans..Immunol Cell Biol2010;88:376-80 PMCID:PMC2865578

[8] Gardner A.Dendritic cells and cancer immunity..Trends Immunol2016;37:855-65 PMCID:PMC5135568

[9] Zelenay S.Adaptive immunity after cell death..Trends Immunol2013;34:329-35

[10] Schreibelt G,Sliepen KH,Figdor CG.Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy..Cancer Immunol Immunother2010;59:1573-82

[11] Liu Y.Cancer and innate immune system interactions: translational potentials for cancer immunotherapy..J Immunother2012;35:299-308 PMCID:PMC3331796

[12] Fang H,Xu X,Wu Y.TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells..Cell Mol Immunol2014;11:150-9 PMCID:PMC4003380

[13] Krasnova Y,Smyth MJ.Bench to bedside: NK cells and control of metastasis..Clin Immunol2017;177:50-9

[14] Artis D.The biology of innate lymphoid cells..Nature2015;517:293-301

[15] Morvan MG.NK cells and cancer: you can teach innate cells new tricks..Nat Rev Cancer2016;16:7-19

[16] Pahl J.Tricking the balance: NK cells in anti-cancer immunity..Immunobiology2017;222:11-20

[17] Wang W,Hank JA,Sondel PM.NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy..Front Immunol2015;6:68 PMCID:PMC4515552

[18] Vivier E,Moretta A,Zitvogel L.Innate or adaptive immunity? The example of natural killer cells..Science2011;331:44-9 PMCID:PMC3089969

[19] Stangl S,Sievert W,Niu M.Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Gro..Int J Cancer2018;142:1911-25 PMCID:PMC5873418

[20] Hoshikawa M,Matsushita H,Hosoi A.NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer..Biochem Biophys Res Commun2018;495:2058-65

[21] Murray PJ,Biswas SK,Gilroy DW.Macrophage activation and polarization: nomenclature and experimental guidelines..Immunity2014;41:14-20 PMCID:PMC4123412

[22] DeNardo DG.Macrophages as regulators of tumour immunity and immunotherapy..Nat Rev Immunol2019;19:369-82

[23] Zhang M,Sun X,Wang W.A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients..J Ovarian Res2014;7:1-16 PMCID:PMC3939626

[24] Yuan A,Chen HY,Ho CC.Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression..Sci Rep2015;5:14273 PMCID:PMC4585843

[25] Emens LA,Darcy PK,Eggermont AMM.Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape..Eur J Cancer2017;81:116-29

[26] Schreiber RD,Smyth MJ.Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion..Science2011;331:1565-70

[27] Radvanyi LG,Vaziri H,Shi Y.CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response..J Immunol1996;156:1788-98

[28] Knutson KL.Tumor antigen-specific T helper cells in cancer immunity and immunotherapy..Cancer Immunol Immunother2005;54:721-8

[29] Haabeth OAW,Corthay A.A model for cancer-suppressive inflammation..Oncoimmunology2012;1:1146-55 PMCID:PMC3494627

[30] Burkholder B,Burgess R,Jones VS.Tumor-induced perturbations of cytokines and immune cell networks..Biochim Biophys Acta2014;1845:182-201

[31] Martínez-Lostao L,Pardo J.How do cytotoxic lymphocytes kill cancer cells?.Clin Cancer Res2015;21:5047-56

[32] Lawand M,Dieu-Nosjean MC.Key features of gamma-delta T-cell subsets in human diseases and their immunotherapeutic implications..Front Immunol2017;8:761 PMCID:PMC5491929

[33] Zoine JT,Fleischer LC,Goldsmith KC.Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model..Oncoimmunology2019;8:1593804 PMCID:PMC6682349

[34] Muto M,Maekawa R,Seino KI.Myeloid molecular characteristics of human γ δ T cells support their acquisition of tumor antigen-presenting capacity..Cancer Immunol Immunother2015;64:941-9

[35] Brandes M,Moser B.Professional antigen-presentation function by human gammadelta T Cells..Science2005;309:264-8

[36] Tsou P,Ostrin EJ.The emerging role of B cells in tumor immunity..Cancer Res2016;76:5597-601

[37] Kimiz-Gebologlu I,Biray-Avci C.Monoclonal antibodies in cancer immunotherapy..Mol Biol Rep2018;45:2935-40

[38] McGranahan N.Clonal heterogeneity and tumor evolution: past, present, and the future..Cell2017;168:613-28

[39] Jamal-Hanjani M,Larkin J.Translational implications of tumor heterogeneity..Clin Cancer Res2015;21:1258-66 PMCID:PMC4374162

[40] Hölzel M,Tüting T.Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?.Nat Rev Cancer2013;13:365-76

[41] Disis ML.Immune regulation of cancer..J Clin Oncol2010;28:4531-8 PMCID:PMC3041789

[42] Landsberg J,Renn M,Rogava M.Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation..Nature2012;490:412-6

[43] Snyder A,Merghoub T,Zaretsky JM.Genetic basis for clinical response to CTLA-4 blockade in melanoma..N Engl J Med2014;371:2189-99 PMCID:PMC4315319

[44] Watkins TBK.Phylogenetic quantification of intratumor heterogeneity..Cold Spring Harb Perspect Med2018;8:pii: a028316

[45] Connor ME.Loss of MHC class-I expression in cervical carcinomas..Int J Cancer1990;46:1029-34

[46] Jäger E,Altmannsberger M,Karbach J.Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma..Int J Cancer1997;71:142-7

[47] Khong HT,Rosenberg SA.Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: Tumor escape by antigen loss and loss of MHC expression..J Immunother2004;27:184-90 PMCID:PMC2275330

[48] Verdegaal EME,Visser M,Van Buuren MM.Neoantigen landscape dynamics during human melanoma-T cell interactions..Nature2016;536:91-5

[49] Aptsiauri N,Garrido F.The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses..Curr Opin Immunol2018;51:123-32

[50] Qian J,Yang J,Liu R.TLR2 promotes glioma immune evasion by downregulating MHC class II molecules in microglia..Cancer Immunol Res2018;6:1220-33

[51] Rimsza LM,Miller TP,LeBlanc M.Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular..Blood2004;103:4251-8

[52] Cabrera CM,Cabrera T,Ruiz-Cabello F.Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors..Tissue Antigens2003;61:211-9

[53] Vlková V,Hrušková V,Šrámek M.Epigenetic regulations in the IFNγ signalling pathway : IFNγ- mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes..Oncotarget2014;5:6923-35 PMCID:PMC4196173

[54] Schmiedel D.NKG2D ligands-critical targets for cancer immune escape and therapy..Front Immunol2018;9:2040 PMCID:PMC6141707

[55] Ghadially H,Lloyd C,Lewis A.MHC class i chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue..Br J Cancer2017;116:1208-17 PMCID:PMC5418453

[56] Fernández-Messina L,Valés-Gómez M.A short half-life of ULBP1 at the cell surface due to internalization and proteosomal degradation..Immunol Cell Biol2016;94:479-85

[57] Raneros AB,Colado E,Mogorron AV.Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition..Oncotarget2017;8:31959-76 PMCID:PMC5458262

[58] Boni A,Dang P,Njauw CNJ.Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function..Cancer Res2010;70:5213-9

[59] Frederick DT,Cogdill AP,Lezcano C.BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma..Clin Cancer Res2013;19:1225-31 PMCID:PMC3752683

[60] Peng W,Liu C,Creasy C.Loss of PTEN promotes resistance to T cell-mediated immunotherapy..Cancer Discov2016;6:202-16 PMCID:PMC4744499

[61] Li B,Su Y,Wang Z.Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism..Mol Med Rep2019;20:3793-801 PMCID:PMC6755145

[62] Singh S,Gordetsky J.Docetaxel combined with thymoquinone induces apoptosis in prostate cancer cells via inhibition of the PI3K/AKT signaling pathway..Cancers (Basel)2019;11:E1390 PMCID:PMC6770702

[63] Reed JC.Bcl-2 on the brink of breakthroughs in cancer treatment..Cell Death Differ2018;25:3-6

[64] Marques CA,Wölfel C,Huber C.An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression..Blood2008;111:1413-9

[65] Maruyama R,Itoi T,Bilim V.Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma..Br J Cancer2006;95:1244-9 PMCID:PMC2360577

[66] Delbridge ARD,Strasser A.Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies..Nat Rev Cancer2016;16:99-109

[67] Fanger NA,Schooley K.Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)..J Exp Med1999;190:1155-64 PMCID:PMC2195665

[68] Griffith TS,Kubin MZ,Maliszewski CR.Monocyte-mediated tumoricidal activity via the tumor necrosis factor- related cytokine, TRAIL..J Exp Med1999;189:1343-54 PMCID:PMC2193036

[69] Day TW,Safa AR.c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells..Biochem Pharmacol2008;76:1694-704 PMCID:PMC2610355

[70] Engelsgjerd S,Kandil E,Kunnimalaiyaan M.Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines..PLoS One2019;14:e0213776 PMCID:PMC6417737

[71] Baritaki S,Sakai T,Bonavida B.Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1..Mol Cancer Ther2007;6:1387-99

[72] Huerta-Yepez S,Escoto-Chavez SE,Sakai T.Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1..Nitric Oxide2009;20:39-52

[73] Zang F,Leng X,Sun B.C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancer..Biochem Biophys Res Commun2014;450:267-73

[74] Golks A,Krammer PH.The c-FLIP-NH2 terminus (p22-FLIP) induces NF-κB activation..J Exp Med2006;203:1295-305 PMCID:PMC2121210

[75] Bardhan K,Boussiotis VA.The PD1: PD-L1/2 pathway from discovery to clinical implementation..Front Immunol2016;7:550 PMCID:PMC5149523

[76] Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy..Nat Rev Cancer2012;12:252-64 PMCID:PMC4856023

[77] Arasanz H,Zuazo M,Breckpot K.PD1 signal transduction pathways in T cells..Oncotarget2017;8:51936-45 PMCID:PMC5584302

[78] Hays E.YY1 regulates cancer cell immune resistance by modulating PD-L1 expression..Drug Resist Updat2019;43:10-28

[79] Zhang J,Wang H,Geng Y.Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance..Nature2018;553:91-5 PMCID:PMC5754234

[80] Wang X,Kong L.PD-L1 expression in human cancers and its association with clinical outcomes..Onco Targets Ther2016;9:5023-39 PMCID:PMC4990391

[81] Rudd CE,Schneider H.CD28 and CTLA-4 coreceptor expression and signal transduction..Immunol Rev2009;229:12-26 PMCID:PMC4186963

[82] Mead KI,Manzotti CN,Liu MKP.Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells..J Immunol2005;174:4803-11

[83] Valk E,Kang H,Rudd CE.T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor..Immunity2006;25:807-21

[84] Linsley PS,Brady W,Ledbetter JA.Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors..Immunity1994;1:793-801

[85] Qureshi OS,Nakamura K,Manzotti C.Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4..Science2011;332:600-3 PMCID:PMC3198051

[86] Chen X,Hao S,Wang Y.CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function..Oncotarget2017;8:13703-15 PMCID:PMC5355131

[87] Bengsch F,Liu A,Beatty GL.CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer..Cancer Immunol Immunother2017;66:1609-17 PMCID:PMC5677559

[88] Paget S.The distribution of secondary growths in cancer of the breast..Lancet1889;133:571-3

[89] Wu M,Lou J,Zhang X.TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment..Oncotarget2016;7:44534-44 PMCID:PMC5190116

[90] Zhang S,Zeng S,Lou J.Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment..Cell Mol Immunol2015;12:580-91 PMCID:PMC4579658

[91] Jordan MS,Reed AJ,Holenbeck AE.Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide..Nat Immunol2001;2:301-6

[92] Whiteside TL.FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity..Expert Opin Ther Targets2018;22:353-63 PMCID:PMC6126897

[93] Saito T,Wada H,Sugiyama D.Two FOXP3 + CD4 + T cell subpopulations distinctly control the prognosis of colorectal cancers..Nat Med2016;22:679-84

[94] Strauss L,Whiteside TL.Human circulating CD4 + CD25 high Foxp3 + regulatory T cells kill autologous CD8 + but not CD4 + responder cells by Fas-mediated apoptosis..J Immunol2009;182:1469-80 PMCID:PMC3721355

[95] Tanaka A.Regulatory T cells in cancer immunotherapy..Cell Res2017;27:109-18 PMCID:PMC5223231

[96] Cao X,Fehniger TA,Collins LI.Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance..Immunity2007;27:635-46

[97] Li K,Xie H.Decreased FOXP3+ and GARP+ tregs to neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer..Onco Targets Ther2016;9:3525-33 PMCID:PMC4913533

[98] Curiel TJ,Zou L,Cheng P.Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival..Nat Med2004;10:942-9

[99] Kumar V,Tcyganov E.The nature of myeloid-derived suppressor cells in the tumor microenvironment..Trends Immunol2016;37:208-20 PMCID:PMC4775398

[100] Liu Y,Chen Q,Xu S.MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN..J Immunol2012;188:5500-10

[101] Ostrand-Rosenberg S.Myeloid-derived suppressor cells: linking inflammation and cancer..J Immunol2009;182:4499-506 PMCID:PMC2810498

[102] Ku AW,Powers CA,Kim M.Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes..Elife2016;5:e17375 PMCID:PMC5199197

[103] Gabrilovich DI.Myeloid-derived suppressor cells as regulators of the immune system..Nat Rev Immunol2009;9:162-74 PMCID:PMC2828349

[104] Sinha P,Bunt SK,Ostrand-Rosenberg S.Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response..J Immunol2007;179:977-83

[105] Chen Q,Massagué J.Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs..Cancer Cell2011;20:538-49 PMCID:PMC3293160

[106] Geiger R,Wolf T,Feng Y.L-arginine modulates t cell metabolism and enhances survival and anti-tumor activity..Cell2016;167:829-42 PMCID:PMC5075284

[107] Rodriguez PC,Zabaleta J,Zea AH.Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses..Cancer Res2004;64:5839-49

[108] Ruffell B,Chan V,Ho CMT.Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells..Cancer Cell2014;26:623-37 PMCID:PMC4254570

[109] Kuang DM,Peng C,Zhang JP.Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1..J Exp Med2009;206:1327-37 PMCID:PMC2715058

[110] Lin H,Hurt EM,Zhao L.Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression..J Clin Invest2018;128:805-15 PMCID:PMC5785251

[111] Smith AL,Ford HL.Molecular pathways: targeting the TGF-β pathway for cancer therapy..Clin Cancer Res2012;18:4514-21

[112] Liu VC,Jang T,Park I.Tumor evasion of the immune system by converting CD4 + CD25 - T cells into CD4 + CD25 + T regulatory cells: role of tumor-derived TGF-β..J Immunol2007;178:2883-92

[113] Mangan PR,O’Quinn DB,Bullard DC.Transforming growth factor-β induces development of the T H17 lineage..Nature2006;441:231-4

[114] Tauriello DVF,Stork D,Badia-Ramentol J.TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis..Nature2018;554:538-43

[115] Mariathasan S,Nickles D,Yuen K.TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells..Nature2018;554:544-8 PMCID:PMC6028240

[116] Ito S ei,Kasahara Y,Ishioka C.IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model..Cancer Immunol Immunother2017;66:1485-96

[117] Lamichhane P,Shreeder B,Bahr D.IL10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer..Cancer Res2017;77:6667-78 PMCID:PMC5712245

[118] Fabre J,Garbar C,Merrouche Y.Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type..Int J Mol Sci2016;17:1433 PMCID:PMC5037712

[119] Junttila MR.Influence of tumour micro-environment heterogeneity on therapeutic response..Nature2013;501:346-54

[120] Molon B,Del Pozzo F,Zilio S.Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells..J Exp Med2011;208:1949-62 PMCID:PMC3182051

[121] Finak G,Pepin F,Souleimanova M.Stromal gene expression predicts clinical outcome in breast cancer..Nat Med2008;14:518-27

[122] Facciabene A,Hagemann IS,Barchetti A.Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T reg cells..Nature2011;475:226-30

[123] Osada T,Tansik R,Spector N.The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients..Cancer Immunol Immunother2008;57:1115-24 PMCID:PMC4110970

[124] Calcinotto A,Grioni M,De Milito A.Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes..Cancer Res2012;72:2746-56

[125] Green DR,Pinkoski M.Activation-induced cell death in T cells..Immunol Rev2003;193:70-81

[126] Chhabra A,Batra D.Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53..Expert Opin Ther Targets2017;21:117-29

[127] Scheffel MJ,Simms P,Mehrotra S.Efficacy of adoptive T-cell therapy isimproved by treatment with the antioxidant N-acetyl cysteine, which limits activation-induced T-cell death..Cancer Res2016;70:6006-16 PMCID:PMC5074089

[128] Schulte M,Lettau M,Ludwig A.ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death..Cell Death Differ2007;14:1040-9

[129] Chhabra A.Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy..Vaccine2010;28: PMCID:PMC3870157

[130] Huang D,Yang L,Li J.NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death..Nat Immunol2018;19:1112-25

[131] Firor AE,Ma Y.From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy..Exp Biol Med2015;240:1087-98 PMCID:PMC4935283

[132] June CH,Kawalekar OU,Milone MC.CAR T cell immunotherapy for human cancer..Science2018;359:1361-5

[133] Wang J,Huang H.Current development of chimeric antigen receptor T-cell therapy..Stem Cell Investig2018;5:44 PMCID:PMC6327156

[134] Wang Z,Liu Y.New development in CAR-T cell therapy..J Hematol Oncol2017;10:53 PMCID:PMC5320663

[135] Staff N. With FDA approval for advanced lymphoma, second CAR T-cell therapy moves to the clinic. Natl Cancer Inst 2017. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2017/yescarta-fda-lymphoma [Last accessed on 25 Dec 2019]

[136] Yan Z,Cheng H,Zhang H.A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial..Lancet Haematol2019;6:e521-9

[137] Martinez M.CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment..Front Immunol2019;10:128 PMCID:PMC6370640

[138] Morsut L,Xiong X,Coyle SM.Engineering customized cell sensing and response behaviors using synthetic Notch receptors..Cell2016;164:780-91 PMCID:PMC4752866

[139] Ohaegbulam KC,Lazar-Molnar E,Zang X.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway..Trends Mol Med2015;21:24-33 PMCID:PMC4282825

[140] D’Angelo SP.Manipulating the immune system with checkpoint inhibitors for patients with metastatic sarcoma..Am Soc Clin Oncol Educ B2016;36:e558-64

[141] Bennani-Baiti N,Ansell S.Checkpoint inhibitors for the treatment of hodgkin lymphoma..Expert Rev Clin Immunol2016;12:673-9

[142] Chuang J,Hendifar A,Gong J.Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies..Transl Gastroenterol Hepatol2019;4:63 PMCID:PMC6737389

[143] Ansell SM,Borrello I,Scott EC.PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma..N Engl J Med2015;372:311-9 PMCID:PMC4348009

[144] Weber J,Del Vecchio M,Arance AM.Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma..N Engl J Med2017;377:1824-35

[145] Larkin J,Gonzalez R,Cowey CL.Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma..N Engl J Med2015;373:23-34 PMCID:PMC5698905

[146] Granier C,Blanc C,Badoual C.Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer..ESMO Open2017;2:e000213 PMCID:PMC5518304

[147] Chang CH,O’Sullivan D,Noguchi T.Metabolic competition in the tumor microenvironment is a driver of cancer progression..Cell2015;162:1229-41 PMCID:PMC4864363

[148] O’Donnell JS,Scolyer RA,Smyth MJ.Resistance to PD1/PDL1 checkpoint inhibition..Cancer Treat Rev2017;52:71-81

[149] Gibney GT,Atkins MB.Predictive biomarkers for checkpoint inhibitor-based immunotherapy..Lancet Oncol2016;17:e542-51 PMCID:PMC5702534

[150] Rizvi NA,Snyder A,Makarov V.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer..Science2015;348:124-8 PMCID:PMC4993154

[151] Le DT,Wang H,Kemberling H.PD-1 blockade in tumors with mismatch-repair deficiency..N Engl J Med2015;372:2509-20 PMCID:PMC4481136

[152] Francis DM.Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy..Adv Drug Deliv Rev2017;114:33-42 PMCID:PMC5581991

[153] Gordon S,Garban H.Transcription factor YY1: structure, function, and therapeutic implications in cancer biology..Oncogene2006;25:1125-42

[154] Bonavida B,Vega MI,Baritaki S.Roles each of Snail, Yin Yang 1, and RKIP in the regulation of tumor cells chemo- immuno-resistance to apoptosis..For Immunopathol Dis Therap2013;4:79-92 PMCID:PMC3811117

[155] Rathore R,Varghese E,Büsselberg D.Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)..Apoptosis2017;22:898-919 PMCID:PMC5486846

[156] Mohammad RM,Lowe L,Hsu HY.Broad targeting of resistance to apoptosis in cancer..Semin Cancer Biol2015;35:S78-103 PMCID:PMC4720504

[157] Ma L,Keyoumu Z,Keyoumu S.Immunotherapy of dual-function vector with both immunostimulatory and B-cell lymphoma 2 (Bcl-2)-silencing effects on gastric carcinoma..Med Sci Monit2017;23:1980-91 PMCID:PMC5412972

[158] Soragni A,Johnson LM,Thai-Quynh Nguyen A.A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas..Cancer Cell2016;29:90-103 PMCID:PMC4733364

[159] Baritaki S,Malaponte G,Salcedo M.The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/ RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis..Int J Oncol2011;38:1683-94

[160] Pitt JM,Eggermont A,Kroemer G.Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy..Ann Oncol2016;27:1482-92

[161] Nakamura K.Targeting cancer-related inflammation in the era of immunotherapy..Immunol Cell Biol2017;95:325-32

[162] Marabelle A,Sagiv-Barfi I,Axtell RC.Depleting tumor-specific Tregs at a single site eradicates disseminated tumors..J Clin Invest2013;123:2447-63 PMCID:PMC3668834

[163] Taylor NA,Iglesia MD,Midkiff BR.Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer..J Clin Invest2017;127:3472-83 PMCID:PMC5669567

[164] Dominguez GA,Mony S,Wang F.Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody..Clin Cancer Res2017;23:2942-50 PMCID:PMC5468499

[165] Georgoudaki AM,Boura VF,Sohn S.Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis..Cell Rep2016;15:2000-11

[166] Ngambenjawong C,Pun SH.Progress in tumor-associated macrophage (TAM)-targeted therapeutics..Adv Drug Deliv Rev2017;114: PMCID:PMC5581987

[167] Yang L,Yeung TL,Jiang D.Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth..Cell Metab2016;24:685-700

[168] Lin Z,Luo W.Angiogenesis inhibitors as therapeutic agents in cancer: challenges and future directions..Eur J Pharmacol2016;793:76-81

[169] Hatfield SM,Lukashev D,Belikoff B.Immunological mechanisms of the antitumor effects of supplemental oxygenation..Sci Transl Med2015;7:277ra30 PMCID:PMC4641038

[170] Kim JY.Targeting tumor adaption to chronic hypoxia: implications for drug resistance, and how it can be overcome..Int J Mol Sci2017;18:1854 PMCID:PMC5618503

[171] Fu J,Kadayakkara DK,Pardoll D.Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors..Cancer Res2014;74:4042-52 PMCID:PMC4396709

[172] Chen L,Kleinberg L,Marciscano AE.Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma..Int J Radiat Oncol Biol Phys2018;100:916-25

[173] Lu X,Paul E,Troncoso P.Effective combinatorial immunotherapy for castration-resistant prostate cancer..Nature2017;543:728-32 PMCID:PMC5374023

[174] Pallasch CP,Braun CJ,Drake A.Sensitizing protective tumor microenvironments to antibody-mediated therapy..Cell2014;156:590-602 PMCID:PMC3975171

[175] Cao K,Li W,Wang R.Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity..Oncogene2015;34:5960-70 PMCID:PMC4672172

[176] Nixon NA,Ernst S,Bebb G.Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges..Curr Oncol2018;25:e373-84 PMCID:PMC6209564

[177] Tahmasebi S,Esmaeilzadeh A.Solid tumors challenges and new insights of car t cell engineering..Stem Cell Rev Reports2019;15:619-36

[178] Bol KF,Gerritsen WR,Figdor CG.Dendritic cell-based immunotherapy: state of the art and beyond..Clin Cancer Res2016;22:1897-906

[179] Ardolino M,Iannello A,Horan L.Cytokine therapy reverses NK cell anergy in MHC-deficient tumors..J Clin Invest2014;124:4781-94 PMCID:PMC4347250

[180] Natural killer cells for cancer immunotherapy: a new CAR is catching up..EBioMedicine2019;39:1-2 PMCID:PMC6355444

[181] Vivarelli S,Candido S,Santagati M.Gut microbiota and cancer: from pathogenesis to therapy..Cancers (Basel)2019;11:38 PMCID:PMC6356461

[182] Gopalakrishnan V,Nezi L,Andrews MC.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients..Science2018;359:97-103 PMCID:PMC5827966

[183] Hanauer D,Sinha-Kumar C.Bioinformatics approaches in the study of cancer..Curr Mol Med2007;7:133-41

[184] Trebeschi S,Birkbak NJ,Cǎlin AM.Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers..Ann Oncol2019;30:998-1004